These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 34044551)

  • 21. Role of surgical resection in recurrent glioblastoma: prognostic factors and outcome evaluation in an observational study.
    Pessina F; Navarria P; Cozzi L; Tomatis S; Riva M; Ascolese AM; Santoro A; Simonelli M; Bello L; Scorsetti M
    J Neurooncol; 2017 Jan; 131(2):377-384. PubMed ID: 27826681
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effectiveness of temozolomide treatment used at the same time with radiotherapy and adjuvant temozolomide; concomitant therapy of glioblastoma multiforme: multivariate analysis and other prognostic factors.
    Birol Sarica F; Tufan K; Cekinmez M; Sen O; Cem Onal H; Mertsoylu H; Topkan E; Pehlivan B; Erdogan B; Nur Altinors M
    J Neurosurg Sci; 2010 Mar; 54(1):7-19. PubMed ID: 20436394
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Relationship of glioblastoma multiforme to the subventricular zone is associated with survival.
    Jafri NF; Clarke JL; Weinberg V; Barani IJ; Cha S
    Neuro Oncol; 2013 Jan; 15(1):91-6. PubMed ID: 23095230
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Factor analysis of cerebrospinal fluid spread in glioblastoma].
    Huang J; Li MX; Ma ML; Ren XH; Cui Y; Lin S
    Zhonghua Wai Ke Za Zhi; 2020 Jun; 58(6):469-474. PubMed ID: 32498488
    [No Abstract]   [Full Text] [Related]  

  • 25. Human TERT promoter mutation enables survival advantage from MGMT promoter methylation in IDH1 wild-type primary glioblastoma treated by standard chemoradiotherapy.
    Nguyen HN; Lie A; Li T; Chowdhury R; Liu F; Ozer B; Wei B; Green RM; Ellingson BM; Wang HJ; Elashoff R; Liau LM; Yong WH; Nghiemphu PL; Cloughesy T; Lai A
    Neuro Oncol; 2017 Mar; 19(3):394-404. PubMed ID: 27571882
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Patterns of recurrence according to the extent of resection in patients with IDH-wild-type glioblastoma: a retrospective study.
    Yoo J; Yoon SJ; Kim KH; Jung IH; Lim SH; Kim W; Yoon HI; Kim SH; Sung KS; Roh TH; Moon JH; Park HH; Kim EH; Suh CO; Kang SG; Chang JH
    J Neurosurg; 2022 Aug; 137(2):533-543. PubMed ID: 34972087
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Surgery for Glioblastoma in Light of Molecular Markers: Impact of Resection and MGMT Promoter Methylation in Newly Diagnosed IDH-1 Wild-Type Glioblastomas.
    Gessler F; Bernstock JD; Braczynski A; Lescher S; Baumgarten P; Harter PN; Mittelbronn M; Wu T; Seifert V; Senft C
    Neurosurgery; 2019 Jan; 84(1):190-197. PubMed ID: 29617848
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Optimal Timing of Radiotherapy Following Gross Total or Subtotal Resection of Glioblastoma: A Real-World Assessment using the National Cancer Database.
    Buszek SM; Al Feghali KA; Elhalawani H; Chevli N; Allen PK; Chung C
    Sci Rep; 2020 Mar; 10(1):4926. PubMed ID: 32188907
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Independent association of extent of resection with survival in patients with malignant brain astrocytoma.
    McGirt MJ; Chaichana KL; Gathinji M; Attenello FJ; Than K; Olivi A; Weingart JD; Brem H; Quiñones-Hinojosa AR
    J Neurosurg; 2009 Jan; 110(1):156-62. PubMed ID: 18847342
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Spatial transcriptome analysis reveals Notch pathway-associated prognostic markers in IDH1 wild-type glioblastoma involving the subventricular zone.
    Jungk C; Mock A; Exner J; Geisenberger C; Warta R; Capper D; Abdollahi A; Friauf S; Lahrmann B; Grabe N; Beckhove P; von Deimling A; Unterberg A; Herold-Mende C
    BMC Med; 2016 Oct; 14(1):170. PubMed ID: 27782828
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serum concentrations of glial fibrillary acidic protein (GFAP) do not indicate tumor recurrence in patients with glioblastoma.
    Vietheer JM; Rieger J; Wagner M; Senft C; Tichy J; Foerch C
    J Neurooncol; 2017 Oct; 135(1):193-199. PubMed ID: 28717884
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [The phenomenon of long-term survival in glioblastoma patients. Part I: the role of clinical and demographic factors and an IDH1 mutation (R 132 H)].
    Goryaynov SA; Gol'dberg MF; Golanov AV; Zolotova SV; Shishkina LV; Ryzhova MV; Pitskhelauri DI; Zhukov VY; Usachev DY; Belyaev AY; Kondrashov AV; Shurkhay VA; Potapov AA
    Zh Vopr Neirokhir Im N N Burdenko; 2017; 81(3):5-16. PubMed ID: 28665384
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Subventricular Zone Radiation Dose and Outcome for Glioblastoma Treated Between 2006 and 2012.
    Murchison SC; Wiksyk B; Gossman S; Jensen B; Sayers D; Lesperance M; Truong PT; Alexander A
    Cureus; 2018 Nov; 10(11):e3618. PubMed ID: 30697499
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas.
    Akyerli CB; Yüksel Ş; Can Ö; Erson-Omay EZ; Oktay Y; Coşgun E; Ülgen E; Erdemgil Y; Sav A; von Deimling A; Günel M; Yakıcıer MC; Pamir MN; Özduman K
    J Neurosurg; 2018 Apr; 128(4):1102-1114. PubMed ID: 28621624
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Survival outcomes following repeat surgery for recurrent glioblastoma: a single-center retrospective analysis.
    Perrini P; Gambacciani C; Weiss A; Pasqualetti F; Delishaj D; Paiar F; Morganti R; Vannozzi R; Lutzemberger L
    J Neurooncol; 2017 Feb; 131(3):585-591. PubMed ID: 27844310
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Manganese superoxide dismutase (MnSOD) is a malignant astrocytoma specific biomarker and associated with adverse prognosis in p53 expressing glioblastoma.
    Shwetha SD; Shastry AH; Arivazhagan A; Santosh V
    Pathol Res Pract; 2016 Jan; 212(1):17-23. PubMed ID: 26616112
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Benefit of re-operation and salvage therapies for recurrent glioblastoma multiforme: results from a single institution.
    Azoulay M; Santos F; Shenouda G; Petrecca K; Oweida A; Guiot MC; Owen S; Panet-Raymond V; Souhami L; Abdulkarim BS
    J Neurooncol; 2017 May; 132(3):419-426. PubMed ID: 28374095
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Re-irradiation after gross total resection of recurrent glioblastoma : Spatial pattern of recurrence and a review of the literature as a basis for target volume definition.
    Straube C; Elpula G; Gempt J; Gerhardt J; Bette S; Zimmer C; Schmidt-Graf F; Meyer B; Combs SE
    Strahlenther Onkol; 2017 Nov; 193(11):897-909. PubMed ID: 28616821
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Survival in patients with glioblastoma at a first progression does not correlate with isocitrate dehydrogenase (IDH)1 gene mutation status.
    Tabei Y; Kobayashi K; Saito K; Shimizu S; Suzuki K; Sasaki N; Shiokawa Y; Nagane M
    Jpn J Clin Oncol; 2021 Jan; 51(1):45-53. PubMed ID: 32888020
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Is MGMT promoter methylation to be considered in the decision making for recurrent surgery in glioblastoma patients?
    Pala A; Schmitz AL; Knoll A; Schneider M; Hlavac M; König R; Wirtz CR; Coburger J
    Clin Neurol Neurosurg; 2018 Apr; 167():6-10. PubMed ID: 29425743
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.